Sinobiopharma Signs Export Agreement With U.S. Pharmaceutica...( Kingchem to Act as Agent to ...)

Kingchem to Act as Agent to Find Partner to Co-Develop Company's Chinese Patented Skeletal Muscle Relaxant for North American Markets

LAS VEGAS, April 3 /PRNewswire-FirstCall/ -- Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) ("Sinobiopharma") (the "Company") is pleased to announce that it has signed an export agreement with Kingchem, an international marketing organization headquartered in New Jersey that specializes in custom manufacturing and sourcing of pharmaceuticals. Under the two-year agreement, Kingchem will act as an agent to find a U.S. pharmaceutical company to co-develop Sinobiopharma's Chinese patented new version of Cisatracurim besylate, a non-depolarizing pre-surgical skeletal muscle relaxant, for use in North America. Kingchem will also source buyers in North America and facilitate the export process.

Marketed under the Kutai trademark in China, the Company's formulation of Cisatracurim besylate is the world's first that can be stored at room temperature; competitors' versions must be kept at 2 to 8 degrees C. Compared to other neuromuscular blocking agents, Kutai, which is administered intravenously, is immediate in onset and longer in duration. Kutai captured an estimated 80 percent of the Chinese market within 14 months of its launch in China.

Kingchem is a well-established, respected supplier to the pharmaceutical, nutritional and fine chemical industries in the United States and Europe. With more than a decade of service, Kingchem has been recognized by its customers as a quality and reliable supplier.

"We believe this agreement is a first step in expanding the international marketing of Kutai to help generate increased sales revenues," said Sinobiopharma Vice President, Xuejun Chen.

About Kingchem LLC

Kingchem LLC acts as a third party manufacturer's agent, representing a group of first class manu
'/>"/>